

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

SCULLY, SCOTT, MURPHY & PRESSER  
400 GARDEN CITY PLAZA  
GARDEN CITY, NEW YORK 11530

Telephone: (516) 742-4343  
Facsimile: (516) 742-4366  
E-Mail: [intprop@ssmp.com](mailto:intprop@ssmp.com)

FACSIMILE TRANSMISSION

To: U. S. Patent and Trademark Office Attention: Corrected Filing Receipt  
Date: April 19, 2004  
Fax #: 703-746-9195 Pages 7  
From: SCULLY, SCOTT, MURPHY & PRESSER

Re: Timothy J. Miller, et al.  
U.S. Patent Appln. No. 10/646,874  
RECOMBINANT FELINE CORONAVIRUS S PROTEINS  
Our Docket: 15463ZYXWV

COMMENTS:

The Filing Receipt for the above-identified Patent Application has the Domestic Priority data as claimed by applicant incomplete and should read: **Domestic Priority data as claimed by applicant: This application is a CON of 09/854,799 05/14/2001 PAT 6,642,359 which is a CON of 08/392,459 02/22/1995 PAT 6,280,974 which is a CON of 07/847,018 04/08/1992 ABN; which is a 371 of PCT/US91/08525, filed 11/14/1991; which is a CIP of 07/698,927 5/13/1991 ABN; which is a CIP of 07/613,066 11/14/1990 ABN;**

Please send to us a corrected Filing Receipt with the information as it is shown on the pages to follow.

Thank you.

If there are any problems concerning this facsimile, please call (516) 742-4343 and ask for Nalini at ext. 519.

**CONFIDENTIALITY:** The documents accompanying this facsimile transmission may contain information which is either confidential or legally privileged and is intended only for the authorized use of the individual or entity named above without right of publication or republication, dissemination or disclosure except as expressly set forth or established by course of dealing. All rights are reserved. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or use of the contents of this facsimile is prohibited. If you received this transmission in error, please notify us immediately by telephone to arrange for return of the documents.



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/646,874	08/22/2003	1648	1426	15463ZYXWV (PC9003E)	49	26	3

CONFIRMATION NO. 6784

23389  
SCULLY SCOTT MURPHY & PRESSER, PC  
400 GARDEN CITY PLAZA  
GARDEN CITY, NY 11530

## FILING RECEIPT



\*OC000000011549630\*

Date Mailed: 12/22/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

### Applicant(s)

Timothy J. Miller, Malvern, PA;  
Albert Paul Reed, Exton, PA;  
Sharon R. Klepfer, Clifton Heights, PA;  
Nancy E. Pfeiffer, Seward, NE;  
Brian T. Suiter, Lincoln, NE;  
Elaine V. Jones, Wynnewood, PA;

### Assignment For Published Patent Application

Pfizer, Inc., New York, NY;

### Domestic Priority data as claimed by applicant

This application is a CON of 09/854,799 05/14/2001 PAT 6,642,359  
which is a CON of 08/392,459 02/22/1995 PAT 6,280,974  
which is a CON of 07/847,018 04/08/1992 ABN

### Foreign Applications

If Required, Foreign Filing License Granted: 12/19/2003

Projected Publication Date: 04/01/2004

Non-Publication Request: No

Early Publication Request: No

**Title**

Recombinant feline coronavirus S proteins

**Preliminary Class**

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**IN THE SPECIFICATION:**

Please insert at page 1, line 2, with the following paragraph:

**--Cross Reference To Related Applications**

The present application is a continuation of Application Serial No. 09/854,799, filed May 14, 2001, which is a continuation of Application Serial No. 08/392,459, filed February 22, 1995; which is a continuation of Application Serial No. 07/847,018, filed April 8, 1992, now abandoned; which is a 371 of PCT/US91/08525, filed November 14, 1991; which is a continuation-in-part of Application Serial No. 07/698,927, filed May 13, 1991, now abandoned; which is a continuation-in-part of Application Serial No. 07/613,066, filed November 14, 1990, now abandoned.--

Please amend the paragraph beginning on page 8, line 7, as follows:

~~Figure 3 (3-1 to 3-2) illustrates~~ Figures 3A-3B illustrate the nucleotide {(SEQ ID NO: 19)} and amino acid sequence {(SEQ ID NO: 20)} of the PCR expression clone AR58-3.

Please amend the paragraph beginning on page 8, line 10, as follows:

~~Figure 4 (4-1 to 4-12) illustrates~~ Figures 4A-4L illustrate the S gene nucleotide and amino acid sequences of DF2 FIPV {(SEQ ID NO: 21 and 22)}. Also illustrated is a fragment of the sequences of DF2-HP {(SEQ ID NO: 23 and 24)} which are identical to the sequences of DF2 FIPV (to the extent DF2 FIPV has been sequenced) with the exception of the nucleotide changes above and amino acid differences below the DF2-HP sequences.

Please amend the paragraph beginning on page 8, line 17, as follows:

~~Figure 5 (5-1 to 5-12) illustrates~~ Figures 5A-5L illustrate a fragment of the S gene TS-BP nucleotide sequence {(SEQ ID NO: 27)} and amino acid sequence {(SEQ ID NO: 28)} by

PTO-103X  
(Rev. 11-86)

## FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	GRP. ART. UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
07/847,018	04/08/92	1806	\$2,096.00	14532-CIP-2	30	50	11

WILLIAM T. KING  
SMITHKLINE BEECHAM CORPORATION  
CORPORATE PATENTS-U.S., UW2220  
P.O. BOX 1539  
KING OF PRUSSIA, PA 19406-0939

Receipt is acknowledged of the patent application identified herein. It will be considered in its order and you will be notified as to the examination thereof. Be sure to give the U.S. SERIAL NUMBER, DATE OF FILING, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this transmittal.

## Applicant(s)

TIMOTHY J. MILLER, MALVERN, PA; ALBERT P. REED, EXTON, PA; SHARON R. KLEPFER, CLIFTON HEIGHTS, PA; NANCY E. PFEIFFER, SEWARD, NE; BRIAN T. SUITER, LINCOLN, NE; ELAINE V. JONES, WYNNEWOOD, PA.

FOREIGN/PCT APPLICATIONS-PCT

PCT/US91/08525 11/14/91

FOREIGN FILING LICENSE GRANTED 01/05/93  
TITLE  
RECOMBINANT FELINE CORONAVIRUS S PROTEINS  
PRELIMINARY CLASS: 424

RECEIVED  
SMITHKLINE BEECHAM  
CORP. PATENTS-U.S.  
JAN 8 9 35 AM '93

(see reverse)




**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> A61K 39/12, C07K 3/00 C07H 15/12, C12P 21/06 C12Q 1/70, 1/68, A61K 35/14	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/08487</b>  <b>(43) International Publication Date:</b> 29 May 1992 (29.05.92)
<b>(21) International Application Number:</b> PCT/US91/08525 <b>(22) International Filing Date:</b> 14 November 1991 (14.11.91) <b>(30) Priority data:</b> 613,066                      16 November 1990 (16.11.90)    US 698,927                      13 May 1991 (13.05.91)        US <b>(71) Applicant (for all designated States except US):</b> SMITH-KLINE BEECHAM CORPORATION [US/US]; Corporate Patents - U.S., 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> MILLER, Timothy, J. [US/US]; 102 Crestside Way, Malvern, PA 19355 (US). REED, Albert, Paul [US/US]; 117 Baker Circle, Exton, PA 19341 (US). KLEPFER, Sharon, R. [US/US]; 136 N. Glenwood Avenue, Clifton Heights, PA 19018 (US). PFEIFFER, Nancy, E. [US/US]; Route 1, Box 20, Seward, NB 68434 (US). SUITER, Brian, T. [US/US]; 6211 South 42nd Street, Lincoln, NB 68516 (US). JONES, Elaine, V. [US/US]; 1217 Andover Road, Greenhill Farms, PA 19151 (US).		<b>(74) Agents:</b> KING, William, T. et al.; SmithKline Beecham Corporation, Corporate Patents - U.S. (UW2220), 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> RECOMBINANT FELINE CORONAVIRUS S PROTEINS  <b>(57) Abstract</b>  Novel galactokinase/FIPV S fusion proteins and their use as vaccine components, therapeutic agents, diagnostic agents, as well as methods of making same are provided.		

RECEIVED  
SMITHKLINE BEECHAM  
CORP. - U.S.

Oct 21 11 04 AM '92

PATRICK A. SCHRECK SMITHKLINE BEECHAM CORPORATION CORPORATE PATENTS-U.S. UW2220 P. O. BOX 1539 KING OF PRUSSIA, PA 19406-0939		UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) NOTIFICATION OF ACCEPTANCE OF APPLICATION UNDER 35 U.S.C. 371 AND 37 CFR 1.494 OR 1.495
		Date of Mailing 15 October 1992
		File Reference 14532
IDENTIFICATION OF THE INTERNATIONAL APPLICATION		
International application Number PCT/US91/08525	International filing date 14 NOV 1991	Priority date claimed 14 NOV 1990
Applicant for DO/EO/US MILLER, TIMOTHY J.		
NOTIFICATION		
<p>The applicant is hereby advised that the United States Patent and Trademark Office in its capacity as a <input checked="" type="checkbox"/> Designated Office, <input type="checkbox"/> Elected Office, has determined that the above identified international application has met the requirements of 35 U.S.C. 371 and 37 CFR <input checked="" type="checkbox"/> 1.494, <input type="checkbox"/> 1.495 and is ACCEPTED for national patentability examination in the United States Patent and Trademark Office.</p> <p>The United States Serial Number assigned to the application and the relevant dates are:  <u>07/897018</u>      <u>08 APR 1992</u>      <u>08 APR 1992</u>          U.S. NATIONAL SERIAL NO.      35 U.S.C. 102(e) DATE      DATE OF RECEIPT 35 U.S.C. 371 REQUIREMENTS</p> <p><input type="checkbox"/> A request for immediate examination under 35 U.S.C. 371 (f) was received on _____ and the application will be examined in turn.</p> <p><input checked="" type="checkbox"/> No request for immediate examination under 35 U.S.C. 371(f) was received. The application will not be processed or examined before the time limit set forth in either <input type="checkbox"/> PCT Article 23 (Chapter I of the PCT), or <input type="checkbox"/> PCT Article 40 (Chapter II of the PCT) whichever is applicable.</p>		
UNITED STATES DESIGNATED/ELECTED OFFICE		
ADDRESS ONLY: COMMISSIONER OF PATENTS AND TRADEMARKS Box PCT, Attn. DO/EO/US Washington, D.C. 20231		AUTHORIZED OFFICER 

Form PCT/DO/EO/903 (U.S. Version) (April 1987)\*

U.S. DEPARTMENT OF COMMERCE - PTO